Dr. Gregory T. Armstrong on Improved Outcomes for Childhood Cancer Survivors
Gregory T. Armstrong, MD, MSCE, pediatric oncologist, St. Jude Children's Research Hospital, discusses a trial of 34,000 childhood cancer survivors.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512